BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33121237)

  • 1.
    Pozzo F; Bittolo T; Tissino E; Vit F; Vendramini E; Laurenti L; D'Arena G; Olivieri J; Pozzato G; Zaja F; Chiarenza A; Di Raimondo F; Zucchetto A; Bomben R; Rossi FM; Del Poeta G; Dal Bo M; Gattei V
    Haematologica; 2021 Dec; 106(12):3125-3135. PubMed ID: 33121237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS.
    Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
    Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
    Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
    Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.
    Sadria R; Motamed N; Saberi Anvar M; Mehrabani Yeganeh H; Poopak B
    Cancer Rep (Hoboken); 2023 Mar; 6(3):e1757. PubMed ID: 36411516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.
    Pozzo F; Bittolo T; Arruga F; Bulian P; Macor P; Tissino E; Gizdic B; Rossi FM; Bomben R; Zucchetto A; Benedetti D; Degan M; D'Arena G; Chiarenza A; Zaja F; Pozzato G; Rossi D; Gaidano G; Del Poeta G; Deaglio S; Gattei V; Dal Bo M
    Leukemia; 2016 Jan; 30(1):182-9. PubMed ID: 26165233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered DNA Methylation Profiles in
    Pacholewska A; Grimm C; Herling CD; Lienhard M; Königs A; Timmermann B; Altmüller J; Mücke O; Reinhardt HC; Plass C; Herwig R; Hallek M; Schweiger MR
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of SF3B1 mutations in CLL on the DNA-damage response.
    Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
    Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
    Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
    Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
    Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
    Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    López-Oreja I; Gohr A; Playa-Albinyana H; Giró A; Arenas F; Higashi M; Tripathi R; López-Guerra M; Irimia M; Aymerich M; Valcárcel J; Bonnal S; Colomer D
    Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37562845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
    Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
    Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
    Dreger P; Schnaiter A; Zenz T; Böttcher S; Rossi M; Paschka P; Bühler A; Dietrich S; Busch R; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Stilgenbauer S
    Blood; 2013 Apr; 121(16):3284-8. PubMed ID: 23435461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
    Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
    Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients.
    Mitsui T; Koiso H; Nakahashi H; Saitoh A; Shimizu H; Ishizaki T; Ogawa Y; Takizawa M; Yokohama A; Saitoh T; Jinbo T; Ogura H; Handa H; Sawamura M; Sakura T; Karasawa M; Murakami H; Nojima Y; Tsukamoto N
    Int J Hematol; 2016 Feb; 103(2):219-26. PubMed ID: 26588928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.
    Arruga F; Gizdic B; Serra S; Vaisitti T; Ciardullo C; Coscia M; Laurenti L; D'Arena G; Jaksic O; Inghirami G; Rossi D; Gaidano G; Deaglio S
    Leukemia; 2014 May; 28(5):1060-70. PubMed ID: 24170027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
    Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
    Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
    Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.